REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) for an aggregate of 1,625,000 shares of Pulmonx's common stock to two individuals hired by Pulmonx in the fourth quarter of 2025, including Pulmonx's Chief Financial Officer and Chief Operating Officer, Derrick Sung. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
